Trials / Terminated
TerminatedNCT00288522
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2006-02-08
- Last updated
- 2020-06-02
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00288522. Inclusion in this directory is not an endorsement.